2016 | Fourth Midkine Symposium Delegate


   

Back to Program

   
Associate Professor Graham Robertson
   
 

Head of Research & Development

Cellmid Limited, Sydney Australia

www.cellmid.com.au 

Graham Robertson is currently head of R&D at Cellmid where he is pursuing a clinical development program focussed on midkine therapeutics and diagnostics. He brings to this role many years research experience in multiple biological and pathophysiological processes incorporating both clinical studies and diverse experimental approaches. A feature of his recent research has been the application of systems biology approaches including transcriptomic, proteomic and metabolomic profiling techniques to understand complex inter-organ signalling involved in chronic inflammatory diseases.

Graham Robertson gained his PhD in molecular virology from Macquarie University, Australia before undertaking Post-Doctoral training in gene regulation and nuclear architecture at the University of Oxford. He returned to Australia as a Post-Doc in the laboratory of Prof Emma Whitelaw at University of Sydney where he set up a transgenic mouse facility and discovered repeat-induced silencing as an epigenetic process on mammalian transgenes. Graham then moved to Westmead Hospital Millennium Institute where he pursued studies on the fibrotic liver disease NASH and the impact of inducible xenobiotic/drug interactions on drug clearance pathways. A component of this work involved creating a transgenic mouse model for studying gene regulation of human CYP3A4, the main pathway for drug metabolism, that was commercially developed as a screening tool for drug development.

At the ANZAC and Garvan Institutes in Sydney, his main research between 2004-2014 was to explore the impact of cancer-associated inflammation in repressing drug clearance leading to excessive toxicity and also disrupted energy metabolism as the basis for cancer cachexia. A key discovery from this work was the activation of thermogenesis in white & brown fat, linked to body wasting. These findings were published in Cancer Research and Cell Metabolism where it was ranked amongst the 10th highest papers in the latter journal. He has published ~60 papers with >3,000 citations.


 


Thursday 28 April, 11:00am-11:30am (Session 2)

   

Targeting midkine in murine models of kidney disease